生物谷(833266) - 2024 Q4 - 年度业绩

Financial Performance - The total revenue for the reporting period was CNY 516,232,107.07, a decrease of 17.05% compared to the previous year[4] - The net profit attributable to shareholders was CNY -68,883,069.87, representing a decline of 464.60% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -75,357,038.91, down 228.80% from the previous year[4] - The basic earnings per share were CNY -0.56, a decrease of 460.00% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 1,149,313,345.38, a decline of 6.99% year-on-year[6] - The equity attributable to shareholders was CNY 930,595,180.34, down 6.89% compared to the beginning of the period[6] Bad Debt Provision - The company recorded a bad debt provision of CNY 66.82 million during the reporting period, compared to CNY 43.69 million in the previous period[7] Revenue Decline Factors - The decline in revenue was primarily due to price reductions for core products, including the "Dengzhanbai Capsule" and "Dengzhanxixin Injection" due to intensified competition in the healthcare environment[7] Corporate Governance - The company plans to continue monitoring and addressing the fund occupation issues with its former controlling shareholder, Shenzhen Jinsijiang Investment Co., Ltd.[8] Investment Caution - The financial data presented is preliminary and has not been audited, and investors are advised to be cautious regarding investment risks[9]